Raily Aesthetic Medicine Announces Equity Interest Reduction in Subsidiary Following New Investment Agreement

Reuters
Jul 04
Raily Aesthetic Medicine Announces Equity Interest Reduction in Subsidiary Following New Investment Agreement

Raily Aesthetic Medicine International Holdings Ltd. has announced a significant transaction involving a reduction in its equity interest in a subsidiary, the Target Company, from 100% to 30%. This comes as a result of an Investment Agreement entered into by Hangzhou Raily, a wholly-owned subsidiary of Raily Aesthetic, and two investors. The transaction involves a capital injection of RMB5,005,000 by the investors and a capital reduction of RMB2,855,000 by Hangzhou Raily. Following the completion of the transaction, the Target Company will be owned 10% by the First Investor, 60% by the Second Investor, and 30% by Hangzhou Raily. The transaction is expected to result in a gain of RMB528,000 and is anticipated to have a positive financial impact on Raily Aesthetic Medicine International Holdings Ltd. The company believes that the terms of the transaction are fair and beneficial for its future prospects and overall interests.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Raily Aesthetic Medicine International Holdings Ltd. published the original content used to generate this news brief on July 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10